Hypotensive Drugs
PreclinicalSmall molecule
Hypotensive Drugs is one of 34 small molecule programs targeting Adenoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Adenoma
#DrugCompanyPhaseTrials
1Dostinex
PfizerApproved
Orilissa
AbbVieApproved
Nolvadex
AstraZenecaApproved
Octreotide Lar
NovartisApproved
Duragesic
CCephalon
Approved
Lifyorli (copackaged)
CCorcept Therapeutics
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Lanreotide PRF
IpsenPhase 3
Olumiant
Eli LillyPhase 2
Selenium
SSWOG Cancer Research Network
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2030
Recruiting
Adenoma
NCT05991856
Clinical
Trials by Indication[1]
Adenoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hypotensive Drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details